Preparing For Expansion: Perrigo Sets $500M Private Offering, Bausch + Lomb IPO Details Filed
Executive Summary
Perrigo intends to use net proceeds from $500m private offering along with cash on hand and funds from previous credit facilities to finance acquisition of HRA Pharma. Bausch Health reduces debt by $200m as it prepares to target proceeds from planned Bausch + Lomb IPO also to paying down debt.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Pivoting From Planning Changes To Parsing Results
Inflation's impact on consumer spending will be front and center in sector’s quarterly reports, beginning with J&J on 19 April. Potential impact also from price hikes common from most firms since early 2021 in response to increasing costs. Russia’s invasion of Ukraine also will prompt comment.
In Flip Of Bausch Health’s Planned Order For IPOs, Bausch + Lomb Registration Comes Before Solta
“We are positioned to move forward with either the Bausch + Lomb or Solta IPO quickly when market conditions are right for each of them,” CEO Joseph Papa says at J.P. Morgan conference, but the firm’s “next step” in the process of separating the two businesses was filing with the SEC an IPO registration for Bausch + Lomb.
Bausch + Lomb IPO Will Open Tap Further For Paying Down Bausch Health Debt
Paying down Bausch Health’s debt, incurred during previous management’s expansion-by-acquisition strategy when the firm operated as Valeant, has been a box to check from the start of preparing to separate Bausch + Lomb, says CEO Joseph Papa.